Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis - Poll - MDSpire

Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis

  • By

  • Sophie Buhelt

  • Malene Bredahl Hansen

  • Helle Bach Søndergaard

  • Sahla El Mahdaoui

  • Marie Mathilde Hansen

  • Mie Reith Mahler

  • Jeppe Romme Christensen

  • Finn Sellebjerg

  • June 5, 2026

  • 0 min

Share

Original Source(s)

Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis

  • by Sophie Buhelt, Malene Bredahl Hansen, Helle Bach Søndergaard, Sahla El Mahdaoui, Marie Mathilde Hansen, Mie Reith Mahler, Jeppe Romme Christensen, Finn Sellebjerg

  • June 5, 2026

Related Content

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis

An Oxidative Glial Profile as a Predictor of Disability and Cognitive Decline in Primary Progressive Multiple Sclerosis

A network meta-analysis of the performance of acupoint stimulation therapy in improving fatigue, neurological function, and activities of daily living in patients with multiple sclerosis